DGLA Composition for Early Allergic Rhinitis Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing reports suggest that dihomo-γ-linolenic acid (DGLA) can suppress atopic dermatitis in mice, but there is no common technical knowledge on its effectiveness in alleviating or preventing allergic rhinitis or allergic conjunctivitis, such as Japanese cedar pollinosis.
Innovation Solution
A composition comprising DGLA as an active ingredient is administered orally to subjects experiencing nasal or eye discomfort due to allergic rhinitis or allergic conjunctivitis, particularly at the early stage of pollen dispersal, to reduce symptoms like sneezing, nasal discharge, and itchy eyes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DGLA is administered to suppress atopic dermatitis in mice, then dermatitis symptoms are reduced, but there is no demonstrated effect on other allergic diseases such as allergic rhinitis or allergic conjunctivitis
Solution Approach 1:
The patent changes the parameter of application scope from单一的atopic dermatitis to multiple allergic diseases including allergic rhinitis and allergic conjunctivitis. Clinical trials demonstrated that DGLA administration (4mg/kg/day or more) effectively reduced symptom scores for nasal discharge, nasal congestion, itchy eyes, and tearing in subjects with various allergic conditions, thereby expanding the versatility of DGLA while maintaining its proven effectiveness.
2Reliability
If DGLA intake is increased to ensure therapeutic effect, then symptom suppression improves, but the dosage requirement of 4mg/kg/day or more may increase cost and complexity of administration
Solution Approach 1:
The patent employs self-service by utilizing foodstuffs that naturally contain DGLA or DGLA-rich ingredients. Subjects can achieve the therapeutic dosage of 4mg/kg/day or more through dietary intake of these functional foods, eliminating the need for complex pharmaceutical administration systems. This approach maintains reliable symptom suppression while simplifying the complexity of dosage delivery.
3Reliability
If DGLA is used for oral administration to reduce allergic symptoms, then quality of life improves, but the mechanism of action in allergic rhinitis and conjunctivitis differs from the adipocyte suppression mechanism in dermatitis
Solution Approach 1:
The patent applies preliminary action by administering DGLA before the pollen dispersal period begins. Clinical trials showed that starting DGLA intake prior to pollen season and continuing through it maximizes the reduction of allergic symptoms. This proactive approach improves quality of life by preventing symptom escalation, even though the specific immunological mechanisms in allergic rhinitis and conjunctivitis differ from the adipocyte-mediated mechanism in atopic dermatitis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The intake of DGLA effectively reduces the severity of allergic rhinitis or allergic conjunctivitis symptoms, including sneezing, nasal congestion, and itchy eyes, by suppressing the increase in symptom scores and improving quality of life indicators.
Implementation Method 1
γ-linolenic acid is converted into the DGLA and further metabolized by cyclooxygenase to produce prostaglandin E1 (PGE1), which antagonizes prostaglandin E2
Implementation Method 2
DGLA is metabolized by 15-lipoxygenase to produce 15-hydroxyeicosatrienoic acid (15-HETrE), which inhibits 5-lipoxygenase
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides a composition for alleviating or preventing a symptom of allergic rhinitis or allergic conjunctivitis, the composition containing dihomo-γ-linolenic acid (DGLA) as an active ingredient.